ClinicalTrials.gg
CompletedNCT06054698Updated May 22, 2026

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

A Phase 2 interventional study of HRS9531 injection and HRS9531 injection Placebo in Overweight or Obesity, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 4 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing ribupatide in Obesity — 2 open to participants now, 9 under way, 6 of them phase 3. ribupatide · Obesity.

Enrollment
14th of 16
61 · median 142
Started
2023
with 1 other
Phase 2
4 of 16
none open now
Registered
2nd of 16
by date
Lead sponsor
9 of 16
Fujian Shengdi Pharmaceutical Co., Ltd.

Among the 16 studies testing ribupatide in Obesity, this one is the 14th largest by enrollment, is one of 2 that started in 2023, is one of 4 in phase 2, and was the 2nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 16 studies testing ribupatide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ribupatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing ribupatide in Obesity, or all of them as a file.
02

Study summary

To assess the efficacy of HRS9531 injection compared with placebo in weight reduction in overweight or obese subjects after 36 weeks of treatment.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 61 is close to the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. Male or female subjects, 18-65 years of age at the time of signing informed consent.
  3. 28.0 ≤≤ 40.0 kg/m2 or 24 ≤BMI\< 28.0 kg/m2 with at least 1 weight-related comorbidity at screening visit.
  4. Diet and exercise control for at least 3 months before screening visit, and less than 5 kg self-reported change within the last 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Presence of - lab or results that may affect the evaluation of the efficacy or safety of the study drug at screening visit.
  2. poor-controlled hypertension.
  3. PHQ-9 score ≥15.
  4. Medical history of illness that affects weight.
  5. History of diabetes.
  6. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening.
  7. History of acute cardiovascular and cerebrovascular diseases.
  8. Any organ-system developed within 5 years except cured local basal cell carcinoma of skin and cervical carcinoma in situ.
  9. Confirmed or suspected depression, bipolar disorder, suicidal tendency, schizophrenia, or other serious mental illness.
  10. History of alcohol , medication or drug abuse within 1 year prior to screening.
  11. Use of any medication or treatment that may cause significant weight change within 3 months.
  12. History of bariatric surgery.
  13. Subjects participating in /QTc studies need to comply with relevant examinations.
  14. Known or suspected to trial product(s) or related products.
  15. Participation in other clinical trials within 3 month prior to screening.
  16. History of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening
  17. Surgery is planned during the trial.
  18. Mentally incapacitated or speech-impaired.
  19. Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate method.
  20. Researchers and relevant staff of the research Centre or other people directly involved in the implementation of the programme, and their immediate family members.
  21. In the judgment of the investigator, there are circumstances that affect the safety of the subject or any other interference with the evaluation of the test results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    HRS9531 injection

    Drug: HRS9531 injection

  • Placebo comparator
    HRS9531 injection Placebo

    Drug: HRS9531 injection Placebo

Interventions

  • HRS9531 injection , QW,36 weeks

  • DrugHRS9531 injection Placebo

    HRS9531 injection Placebo,QW,36 weeks

07

What researchers measure

Primary outcomes

  1. Percentage change in body weight

    Time frame: Week 0, Week 36

Secondary outcomes

  1. Proportion of Subjects with weight loss of ≥5% from baseline in body weight after 36 weeks of treatment

    Time frame: Week 36

  2. Proportion of Subjects with weight loss of ≥10% from baseline in body weight after 36 weeks of treatment

    Time frame: Week 36

  3. Proportion of Subjects with weight loss of ≥15% from baseline in body weight after 36 weeks of treatment

    Time frame: Week 36

  4. Change from baseline in body weight after 36 weeks of treatment

    Time frame: Week 0, Week 36

  5. Change from baseline in waist circumference after 36 weeks of treatment

    Time frame: Week 0, Week 36

  6. Change from baseline in BMI after 36 weeks of treatment

    Time frame: Week 0, Week 36

  7. Change from baseline in blood pressure after 36 weeks of treatment

    Time frame: Week 0, Week 36

  8. Change from baseline in total cholesterol after 36 weeks of treatment

    Time frame: Week 0, Week 36

  9. Change from baseline in fasting plasma glucose (FPG) after 36 weeks of treatment

    Time frame: Week 0, Week36

  10. Change from baseline in glycosylated haemoglobin (HbA1c) after 36 weeks of treatment

    Time frame: Week 0, Week 36

  11. Number of AEs During the Trial

    Time frame: Week 0 to Week 36

08

Study locations

4 sites
  • The Affiliated Hospital of Xuzhou Medicine University
    Xuzhou, Jiangsu 221000, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Zhejiang Hospital
    Hangzhou, Zhejiang 310007, China
  • Sir Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Sep 2024, 10 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 10 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Sep 26, 2023
StartActual
Oct 16, 2023
Primary completionActual
Sep 9, 2024
CompletionActual
Sep 9, 2024
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06054698
Responsible party
Sponsor
First posted
Sep 26, 2023
Start date
Oct 16, 2023
Primary completion
Sep 9, 2024
Completion
Sep 9, 2024
Last update
May 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion